238 related articles for article (PubMed ID: 9636585)
1. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
[No Abstract] [Full Text] [Related]
2. FK506 for primary and rescue therapy following liver transplantation.
Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
[No Abstract] [Full Text] [Related]
3. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.
Langrehr JM; Klupp J; Junge G; Jonas S; Neuhaus R; Bechstein WO; Neuhaus P
Transplant Proc; 2001 May; 33(3):2330-1. PubMed ID: 11377549
[No Abstract] [Full Text] [Related]
4. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
[No Abstract] [Full Text] [Related]
5. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
[No Abstract] [Full Text] [Related]
6. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation.
Salizzoni M; Cavallari A; Risaliti A; Filipponi F; Gerunda GE; Forti D; Fassati LR; Cillo U; Castagneto M; Valente U; Tisone G
Transplant Proc; 2001 May; 33(3):2258-62. PubMed ID: 11377521
[No Abstract] [Full Text] [Related]
7. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation.
Langrehr JM; Klupp J; Pfitzmann R; Neumann U; Lohmann R; Jonas S; Neuhaus R; Steinmüller T; Neuhaus P
Transplant Proc; 2001; 33(1-2):1520. PubMed ID: 11267404
[No Abstract] [Full Text] [Related]
8. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
9. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
[No Abstract] [Full Text] [Related]
10. Reduction of early rejection in adult liver transplantation with ATG induction therapy.
Schulak J; May E; Post A; Fasola C; Mulligan D; Sterling R
Transplant Proc; 1997; 29(1-2):555-6. PubMed ID: 9123126
[No Abstract] [Full Text] [Related]
11. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
[No Abstract] [Full Text] [Related]
12. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial.
Neuhaus P; Klupp J; Langrehr JM; Neumann U; Gebhardt A; Pratschke J; Tullius SG; Lohmann R; Radke C; Rayes N; Neuhaus R; Bechstein WO
Transplantation; 2000 Jun; 69(11):2343-53. PubMed ID: 10868638
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of various immunosuppressive regimes in second renal transplants.
Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
[No Abstract] [Full Text] [Related]
14. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
15. Prospective evaluation of a quadruple therapy based on tacrolimus after liver transplantation.
Lladó L; Figueras J; Ramos E; Lama C; Busquets J; Ibáñez L; Rafecas A; Fabregat J; Torras J; Jaurrieta E
Transplant Proc; 2002 Feb; 34(1):108. PubMed ID: 11959210
[No Abstract] [Full Text] [Related]
16. Does initial graft function influence the outcome after liver transplantation?
Mueller AR; Platz KP; Krause P; Neuhaus R; Lobeck H; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1464-5. PubMed ID: 9636594
[No Abstract] [Full Text] [Related]
17. One hundred children treated with tacrolimus after primary orthotopic liver transplantation.
McDiarmid S; Goss J; Seu P; Shackleton C; Vargas J; Ament M; Busuttil R
Transplant Proc; 1998 Jun; 30(4):1397-8. PubMed ID: 9636564
[No Abstract] [Full Text] [Related]
18. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
Langrehr JM; Neuhaus PJ
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
[No Abstract] [Full Text] [Related]
19. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis.
Kumar MS; Cahill K; Kumar AM; Panigrahi D; Seirka D; Singleton R; al-Abdullah IH; Laskow DA
Transplant Proc; 1998 Jun; 30(4):1351-2. PubMed ID: 9636549
[No Abstract] [Full Text] [Related]
20. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
[No Abstract] [Full Text] [Related]
[Next] [New Search]
